Search PubMed⌕ Search

Biomedical subjects

Y Harada

Publications and source records attributed to Y Harada.

At least 649 records · Page 36Linked to original sources
PubMed1987

[Giant, fusiform and dissecting aneurysms at the vertebro-basilar junction--report of five cases and their clinical pathophysiological aspects].

Five cases of giant, fusiform, and dissecting aneurysms of the vertebro-basilar junction, in which direct surgical treatment was not feasible, are reported. Their initial symptoms were as follows: 3 subarachnoid hemorrhages (2 fusiform aneurysms, 1 giant aneurysm), 1 mass sign (giant aneurysm), and 1 ischemic sign (dissecting aneurysm). In two patients, one with a giant and one with a dissecting aneurysm, preoperative proximal vertebral occlusion was carried out by inflated balloon for 30 to 100 minutes, under observation of clinical signs and measurement of distal arterial pressure. This catheter technique with an inflated balloon provides the means to assess the effect of vertebral artery occlusion in the alert patient, and to determine if occlusion is tolerated or not. In one case with a giant aneurysm, the proximal vertebral artery was occluded extracranially with no complications and no recurrent subarachnoid hemorrhage for 1 year. The other four patients (1 thrombosed giant aneurysm, 2 fusiform aneurysms, 1 dissecting aneurysm) whose contralateral vertebral arteries were hypoplastic, and who refused to operation, were treated conservatively for 6 months to 6 years. Their outcomes were better than expected, with no recurrent subarachnoid hemorrhage nor aggravation of clinical symptoms except for the one case with a dissecting aneurysm whose deterioration was presumed attributable to late cerebellar cortical atrophy.

Aortic Dissection↗
PubMed1987

[Clinical features and significance of hypertrophic cardiomyopathy with atrial fibrillation].

To elucidate the clinical features of hypertrophic cardiomyopathy (HCM) with atrial fibrillation (Af), the complications and prognosis of 18 patients with HCM complicated by Af (Af group) were compared with those of 20 patients without Af (non-Af group). The Af group was categorized depending on duration as 1. Af group I (four patients) with persistent Af at diagnosis, 2. Af group II (10 patients) with transient Af of more than five hours' duration, and 3. Af group III (four patients) with Af less than five hours' duration. The results were as follows: 1. During the follow-up period, among the 18 patients in the Af group, five including four patients in the Af group I, developed arterial embolism, 10 developed congestive heart failure, and three died suddenly. The patients in the non-Af group had excellent courses without serious complications. 2. Electrical cardioversion was performed in six patients in the Af group II, and sinus rhythm was restored in all of them, resulting in improved clinical courses. Thus, no complications developed in four patients whose sinus rhythm was maintained and whose clinical courses were favorable. 3. The P-terminal force in V1 prior to onset of Af in the Af groups II and III, left atrial dimension, and the cardiothoracic ratio in the Af group, were significantly greater than that of the non-Af group (p less than 0.01, p less than 0.05, p less than 0.05, respectively). In conclusion, HCM associated with Af has a poor prognosis, with severe complications such as heart failure, arterial embolism and sudden death. Cardioversion may be an effective method of choice of intervention in patients with recently-developed Af. P-terminal force in V1, left atrial dimension, and cardiothoracic ratio are regarded important factors in the development of Af.

Adult↗
PubMed1987

[Clindamycin-2-phosphate in the treatment of respiratory infections and its distribution into pleural effusion].

We treated pneumonia due to anaerobic bacteria, Mycoplasma pneumonia, and other type of pneumonia with clindamycin-2-phosphate (CLDM-P) and studied the distribution of the drug into pleural effusion. The obtained results are summarized as follows. 1. CLDM-P showed excellent effects in all the treated cases of pneumonia due to anaerobic bacteria and Mycoplasma pneumonia. But the success rate was 50% in cases of other type of pneumonia. We suggest that the drug must be used in due consideration of the types of causative bacteria. 2. Five cases which had developed pleural effusions were treated with intravenous drip of CLDM-P 1,200 mg in 200 ml electrolytic solution to see the distribution into pleural effusions. The results showed that the distribution ratio was 9.0% on the average. Peak levels were 1.86-6.07 micrograms/ml and the concentration was as high as 1.28 micrograms/ml on the average 24 hours after administration.

Adolescent↗
PubMed1987

[A case of prostate cancer with multiple pulmonary metastases].

A 65-year-old man was hospitalized with bloody sputum. His chest X-ray showed multiple nodules in both lung fields. Transbronchial lung biopsy demonstrated a poorly differentiated adenocarcinoma, which suggested that respiratory abnormalities might be metastatic cancer. Because he had noticed pollakisuria and dysuria, urologic consultation was sought. The findings of digital examination, urethrography, and ultrasonotomography suggested that he had an advanced prostate cancer. In addition, tumor markers of prostatic acid phosphatase (PAP), acid phosphatase (ACP), and prostate antigen (PA) showed abnormal titers; 120 ng/dl, 166 IU/l, and 15.4 ng/ml, respectively. The prostate tissue obtained by transperineal biopsy revealed histopathologically adenocarcinoma and positive findings in immunohistochemical staining for PAP and PA as well as the specimens from the lung. Bilateral orchiectomy and medication of 250 mg of DESD daily as an antiandrogen therapy improved respiratory symptoms. One week after the operation, the multiple shadows on the chest X-ray diminished dramatically. Moreover, serum values of PAP and PA also decreased to the normal range. He is alive in a stable condition 6 months after the operation.

Adenocarcinoma↗
PubMed1986

Potentiation of bradykinin-induced nociceptive response by arachidonate metabolites in dogs.

Bradykinin was injected retrogradely into a branch of the splenic artery of lightly anesthetized dogs, and the reflex hypertensive response was used as an indicator of the nociception. The reflex hypertensive response to low doses of bradykinin (less than 1 nmol), but not to high doses (3-5 nmol), was markedly suppressed by infusion of indomethacin (0.54 mumol/min) into the splenic artery. During indomethacin infusion, the reflex hypertensive response to low doses of bradykinin was potentiated dose dependently by the following arachidonic acid metabolites (ED50): prostaglandin (PG)I2 (2.9 nmol) greater than or equal to PGH2 (4.4) greater than PGE2 (14) = thromboxane (TX)A2(15) greater than PGD2 (greater than 100). Leukotrienes B4, C4 and D4 showed practically no activity. This potentiating effect lasted up to 20 min after injection, particularly with PGE2. These results may not exclude the role of PGI2 as a major candidate for involvement in bradykinin-induced nociception, although a selective TX synthetase inhibitor (OKY-046) showed a weak analgesic effect (only 1/30 that of indomethacin).

Animals↗
PubMed1986

Different modes of interaction of bradykinin with prostaglandins in pain and acute inflammation.

A mode of interaction of bradykinin with prostaglandins (PGs) in pain were compared with that in acute inflammation. When pain production was measured as an increase in reflex hypertensive response of the lightly anesthetized dogs after intrasplenic injection of bradykinin, the response was dependent to the doses (0.3-5 nmol) of bradykinin and that by the small doses (0.1-1 nmol) was blocked by intrasplenic infusion of indomethacin (0.54 mumol/min). The response to the threshold dose of bradykinin (0.3 nmol), which was suppressed during the indomethacin infusion, was potentiated by simultaneous injection of exogenous PGs. Order of the potency was PGI2 greater than PGH2 greater than PGE2 = TXA2 much greater than PGD2. Thus, it is clear that bradykinin induced pain through the generation of one of prostaglandins. On the other hand, the activity of bradykinin in plasma leakage was potentiated by simultaneous injection of PGE2, when tested in rabbit skin. In rat carrageenin-induced pleurisy, plasma prekallikrein was activated and high molecular weight (HMW) kininogen, not low molecular weight (LMW) kininogen, was consumed in the pleural cavity in the entire course of the pleurisy. Bradykinin played a role in plasma exudation in the pleurisy, because the plasma leakage was markedly inhibited in the rats, in which prekallikrein and HMW kininogen in plasma were depleted by intravenous bromelain. PGE2 was found in the pleural exudate, but the contribution of PGE2 itself to the plasma exudation seems to be only 10%. On the basis of the bradykinin release in the pleural cavity, once the PGE2 release was superimposed, the maximal plasma leakage was observed, indicating that PGE2 was released independently from bradykinin, and potentiated the plasma leakage by bradykinin.

Animals↗
PubMed1986

Antigenic polymorphism of a serum protein migrating electrophoretically in the alpha region detected by using a strain derived from the Japanese wild mouse (Mus musculus molossinus).

Antigenic specificities of a serum protein from the mouse Mol-A strain (a strain derived from the Japanese wild mouse, Mus musculus molossinus) was studied by gel precipitation with alloantisera produced by reciprocal alloimmunization between Mol-A and BALB/c mice. Alloantigens which migrate immunoelectrophoretically in the alpha region of serum proteins have also been identified. The evidence indicated that this antigenic specificity is controlled by a codominant autosomal locus designated Aph-1. The evidence also suggests that the Aph-1 locus is linked to the alpha locus on chromosome 2.

Alpha-Globulins↗